Key result
Doxorubicin-induced cardiotoxicity is primarily driven by oxidative stress, mitochondrial damage, and calcium overload, and may be mitigated by medications and phytochemicals with antioxidant properties.
Why the study?
Doxorubicin is a highly cardiotoxic anticancer medication that can result in cardiomyopathy, prompting a review of its mechanisms and updated management strategies.
Understanding the molecular mechanisms of doxorubicin-induced cardiotoxicity, particularly oxidative stress and mitochondrial damage, highlights potential therapeutic targets for cardioprotection in cancer patients.
Answers are grounded in this paper and cite their sources.
Antioxidants merit trial evaluation for doxorubicin cardiotoxicity; evidence remains hypothesis-generating and should not yet change practice.
Unfortunately, anticancer medications are extremely harmful to normal cells. Doxorubicin (DOX) is a highly cardiotoxic medication that can result in cardiomyopathy. The most significant mechanism for DOX-induced cardiotoxicity is oxidative stress, while other pathways have also been put forth. This review aims to highlight the mechanisms of DOX-induced cardiotoxicity and the most updated managements. Trustworthy sites such as Google Scholar, PubMed, and Research Gate were used to find the most updated articles. Many titles have been used for searching, such as "doxorubicin and cardiotoxicity," "cardioprotection," and "cardio-protective effects of phytochemicals." Preprints, review articles, and research with meta-analyses were disregarded. Three pathways, including oxidative stress, mitochondrial damage, and calcium excess, were responsible for DOX-induced cardiotoxicity. Cardiotoxicity may be partially caused by cell death, activation of the ubiquitin-ligase-proteasome system, and changes in its gene expression brought on by DOX. In the instance of DOX cardiotoxicity, medications and nutraceuticals with antioxidants and iron chelating properties have been found to have cardio-protective benefits. In conclusion, doxorubicin-treated cancer patients have been linked to cardiotoxicity, making cardioprotection extremely important in these patients. All of the mechanisms included in this review's discussion might provide light on fresh approaches to the treatment and/or prevention of DOX-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Hamaamin et al. (2022) conducted a review in Doxorubicin-induced cardiotoxicity. Cardioprotective agents (medications and phytochemicals) was evaluated. Doxorubicin-induced cardiotoxicity is primarily driven by oxidative stress, mitochondrial damage, and calcium overload, and may be mitigated by medications and phytochemicals with antioxidant properties.
Synapse has enriched 10 related papers. Consider them for comparative context: